Eli Lilly targets India as global supply chain hub for blockbuster drugs

The drugmaker plans to turn India into a global export hub using a billion-dollar investment. This follows surging Mounjaro sales and plans for new treatments.

洞察:
Eli Lilly and Company announced on February 17, 2026, its plan to establish India ININ as a hub for its global supply chain. This initiative is part of a previously committed $1 billion investment in the contract manufacturing sector in India. The United States USUS-based pharmaceutical firm aims to export locally produced drugs worldwide, leveraging India's contract-manufacturing capacity to reshape its supply and distribution for key products.
Visitors stand at the kiosk of Eli Lilly at the BioAsia conference in Hyderabad, India, February 17, 2026. Picture taken with a mobile phone. REUTERS/Sriparna Roy
Visitors stand at the kiosk of Eli Lilly at the BioAsia conference in Hyderabad, India, February 17, 2026. Picture taken with a mobile phone. REUTERS/Sriparna Roy
IUX24

IUX24 提供深度財經、經濟與投資資訊,藉助 AI 發掘全球市場中最重要的信號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場數據、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易信號或經紀服務。投資涉及風險,用戶在作出投資決定前應審慎評估相關資訊。